



Inotek Appoints Paul G. Howes as President and CEO
- Addition of former Bausch & Lomb and Merck Executive completes transformation of management team -

BEVERLY, Mass., October 1, 2008

Inotek Pharmaceuticals Corporation announced today that it has hired Paul G. Howes as President, CEO and Director. Mr. Howes brings more than twenty years of senior level pharmaceutical experience to Inotek, most recently serving as President of the Americas Region for Bausch & Lomb where he had full commercial responsibility for the Vision Care, Surgical and Pharmaceuticals segments in the United States, Canada, Latin America and South America. Prior to Bausch & Lomb, Mr. Howes worked at Merck & Co. Inc. in various senior management roles, including President & CEO of Dupont Merck Pharmaceuticals Inc., President of Merck Frosst Canada, Inc, Executive Director of Hospital Marketing, and Vice President, Sales & Marketing for Specialty Products.

“We are very pleased to have attracted someone of Paul’s caliber at a time when Inotek is advancing multiple programs through clinical development,” said Jerry Karabelas, Inotek’s Chairman of the Board of Directors. “Paul brings a long history of successful enterprise management and his ophthalmology experience at both B&L and Merck will be of particular importance to Inotek. Importantly, with Paul’s hiring, we have completed the transformation of the executive management team and the Company is now well positioned to advance several key candidates through clinical proof of concept.”

“I am excited about the opportunity that Inotek presents as the Company has built a robust engine of cutting edge technology that is now in the process of being validated in the clinic,” said Paul Howes, President and Chief Executive Officer of Inotek. “Inotek’s technologies are focused on large markets with clear unmet needs. I look forward to working with the talented team of scientists and business people assembled at Inotek to advance these products toward the market.”

About Inotek Pharmaceuticals

Inotek is a clinical-stage, drug development company located in Massachusetts with two clinical stage programs, targeting applications in glaucoma and contrast induced nephropathy. The Company’s preclinical programs include products in development for various other ophthalmology indications spanning several therapeutic mechanisms believed to play a role in ocular disease progression. Inotek also has preclinical programs targeting PARP and flagellin with applications in cancer and inflammatory bowel disease.

Contacts:

Jeffrey T. Walsh
EVP and Chief Business Officer
Inotek Pharmaceuticals Corporation
(978) 201-9129

Sarah Cavanaugh
MacDougall Biomedical Communications
(781) 235-3060